Rush Hymenoptera venom immunotherapy:: A safe and practical protocol for high-risk patients

被引:93
|
作者
Sturm, G [1 ]
Kränke, B [1 ]
Rudolph, C [1 ]
Aberer, W [1 ]
机构
[1] Graz Univ, Dept Environm Dermatol & Allergy, A-8036 Graz, Austria
关键词
honeybee venom; Hymenoptera venom allergy; rush immunotherapy; side effects; yellow jacket venom;
D O I
10.1067/mai.2002.129124
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Hymenoptera venom immunotherapy in allergic patients is a well-established treatment modality for the prevention of systemic anaphylactic reactions caused by insect stings. A variety of therapy regimens exists, from conventional to rush and ultrarush modalities that operate on continuous or intermittent schedules. Objective: The aim of this study was to report the 8-year experience with our rush venom immunotherapy regimen in predominantly high-risk patients and to compare data on safety and convenience with the results of 26 studies published from 1978 to 2001. Methods: One hundred one patients allergic to bee, yellow jacket, or hornet venom were treated with rush Hymenoptera venom immunotherapy. Diagnosis and selection of patients for venom immunotherapy were carried out according to the recommendations of the European Academy of Allergology and Clinical Immunology. We used a 4-day regimen, and the incidence and nature of systemic reactions (SRs) were documented. Fifty-two patients were treated with honeybee venom, and 49 were treated with yellow jacket venom. Results: One hundred (99%) patients reached the maintenance dose. We observed 8 injection-related SRs (0.47% of all injections given) in 7 (6.9%) patients. The number of SRs was higher in patients treated with bee venom extract (12%) compared with in patients receiving yellow jacket venom extract (2%). There was no significant difference in the risk of SRs between female and male patients. The incidence of SRs was considerably lower than the average of 17.8% reported in the literature. Conclusion: With a rush immunotherapy regimen over a time period of 8 years in predominantly high-risk patients, the incidence of SRs was low, despite the high number of patients with bee venom allergy, who are more likely to have side effects. Epinephrine as rescue medication was never necessary, and the regimen proved to be safe and convenient for both the patients and the medical staff.
引用
收藏
页码:928 / 933
页数:6
相关论文
共 50 条
  • [21] Simultaneous Influenza Vaccination and Hymenoptera Venom Immunotherapy Is Safe
    Czerwinska, Ewa
    Nittner-Marszalska, Marita
    Pawlowicz, Robert
    Szenborn, Leszek
    VACCINES, 2021, 9 (04)
  • [22] Rush hymenoptera venom immunotherapy: a means for reduce sICAM-1 levels and allergic inflammation in hymenoptera allergic patients?
    Ricciardi, L.
    Patella, V
    Saitta, S.
    Marotta, G.
    Saija, A.
    Gangemi, S.
    ALLERGY, 2008, 63 : 80 - 81
  • [23] Sublingual immunotherapy with venom for patients with Hymenoptera venom allergy
    Patriarca, Giampiero
    Nucera, Eleonora
    Roncallo, Chiara
    Aruanno, Arianna
    Lombardo, Carla
    Decinti, Marzia
    Pascolini, Lucilla
    Milani, Massimo
    Buonomo, Alessandro
    Schiavino, Domenico
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (02) : 385 - 385
  • [24] Safety of ultra-rush protocol on venom immunotherapy: Evaluation of risk factors for adverse events
    Barradas Lopes, J.
    Santa, C.
    Ferreira, C.
    Mesquita, M.
    Barreira, P.
    Lopes, I
    ALLERGY, 2020, 75 : 101 - 102
  • [25] Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis
    Gonzalez-de-Olano, David
    Alvarez-Twose, Ivan
    Vega, Arantza
    Orfao, Alberto
    Escribano, Luis
    IMMUNOTHERAPY, 2011, 3 (05) : 637 - 651
  • [26] Rush venom immunotherapy in patients experiencing recurrent systemic reactions to conventional venom immunotherapy
    Goldberg, A
    Confino-Cohen, R
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2003, 91 (04) : 405 - 410
  • [27] Tryptase levels during specific immunotherapy with Hymenoptera venom (ultra-rush)
    Palma-Carlos, ML
    Santos, MC
    Pedro, ME
    Ferreira, MB
    Palma-Carlos, AG
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2001, 107 (02) : S114 - S114
  • [28] Ultra-rush immunotherapy: tolerance and efficacy of an aqueous preparation of Hymenoptera venom
    Patella, V
    Florio, G.
    Di Pace, L.
    Palmieri, M.
    Oricchio, C.
    ALLERGY, 2012, 67 : 407 - 407
  • [29] Safety of ultra-rush protocols for hymenoptera venom immunotherapy in systemic mastocytosis
    Gruzelle, Vianney
    Ramassamy, Marion
    Lidiveanu, Cristina Bulai
    Didier, Alain
    Mailhol, Claire
    Guilleminault, Laurent
    ALLERGY, 2018, 73 (11) : 2260 - 2263
  • [30] RUSH VENOM IMMUNOTHERAPY - A 3-DAY PROGRAM FOR HYMENOPTERA STING ALLERGY
    NATAF, P
    GUINNEPAIN, MT
    HERMAN, D
    CLINICAL ALLERGY, 1984, 14 (03): : 269 - 275